VIMTA LABS | KREBS BIOCHEMICALS | VIMTA LABS/ KREBS BIOCHEMICALS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 32.6 | -8.2 | - | View Chart |
P/BV | x | 5.4 | - | - | View Chart |
Dividend Yield | % | 0.3 | 0.0 | - |
VIMTA LABS KREBS BIOCHEMICALS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
VIMTA LABS Mar-24 |
KREBS BIOCHEMICALS Mar-24 |
VIMTA LABS/ KREBS BIOCHEMICALS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 621 | 93 | 666.7% | |
Low | Rs | 317 | 57 | 561.1% | |
Sales per share (Unadj.) | Rs | 143.6 | 23.4 | 613.8% | |
Earnings per share (Unadj.) | Rs | 18.5 | -9.2 | -202.2% | |
Cash flow per share (Unadj.) | Rs | 33.9 | -6.0 | -564.2% | |
Dividends per share (Unadj.) | Rs | 2.00 | 0 | - | |
Avg Dividend yield | % | 0.4 | 0 | - | |
Book value per share (Unadj.) | Rs | 141.2 | -55.3 | -255.3% | |
Shares outstanding (eoy) | m | 22.17 | 21.56 | 102.8% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.3 | 3.2 | 102.1% | |
Avg P/E ratio | x | 25.4 | -8.2 | -310.1% | |
P/CF ratio (eoy) | x | 13.8 | -12.5 | -111.1% | |
Price / Book Value ratio | x | 3.3 | -1.4 | -245.5% | |
Dividend payout | % | 10.8 | 0 | - | |
Avg Mkt Cap | Rs m | 10,402 | 1,614 | 644.6% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 953 | 162 | 589.2% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 3,183 | 504 | 631.2% | |
Other income | Rs m | 40 | 5 | 888.5% | |
Total revenues | Rs m | 3,223 | 509 | 633.5% | |
Gross profit | Rs m | 868 | -87 | -994.9% | |
Depreciation | Rs m | 342 | 68 | 505.4% | |
Interest | Rs m | 21 | 47 | 45.3% | |
Profit before tax | Rs m | 545 | -197 | -276.2% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 135 | 0 | - | |
Profit after tax | Rs m | 410 | -197 | -207.9% | |
Gross profit margin | % | 27.3 | -17.3 | -157.6% | |
Effective tax rate | % | 24.7 | 0 | - | |
Net profit margin | % | 12.9 | -39.1 | -32.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 1,576 | 174 | 903.5% | |
Current liabilities | Rs m | 541 | 618 | 87.4% | |
Net working cap to sales | % | 32.5 | -88.0 | -36.9% | |
Current ratio | x | 2.9 | 0.3 | 1,033.3% | |
Inventory Days | Days | 6 | 64 | 9.0% | |
Debtors Days | Days | 100 | 138 | 72.4% | |
Net fixed assets | Rs m | 2,347 | 1,607 | 146.0% | |
Share capital | Rs m | 44 | 216 | 20.6% | |
"Free" reserves | Rs m | 3,086 | -1,408 | -219.2% | |
Net worth | Rs m | 3,130 | -1,192 | -262.5% | |
Long term debt | Rs m | 91 | 1,835 | 4.9% | |
Total assets | Rs m | 3,923 | 1,782 | 220.1% | |
Interest coverage | x | 26.7 | -3.2 | -831.7% | |
Debt to equity ratio | x | 0 | -1.5 | -1.9% | |
Sales to assets ratio | x | 0.8 | 0.3 | 286.7% | |
Return on assets | % | 11.0 | -8.4 | -130.3% | |
Return on equity | % | 13.1 | 16.5 | 79.2% | |
Return on capital | % | 17.6 | -23.4 | -75.1% | |
Exports to sales | % | 26.6 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | 845 | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 845 | 0 | - | |
Fx outflow | Rs m | 154 | 6 | 2,448.6% | |
Net fx | Rs m | 691 | -6 | -10,985.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 609 | 23 | 2,642.9% | |
From Investments | Rs m | -760 | -78 | 972.9% | |
From Financial Activity | Rs m | -19 | 56 | -34.2% | |
Net Cashflow | Rs m | -171 | 1 | -33,449.0% |
Indian Promoters | % | 36.9 | 72.7 | 50.7% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 3.3 | 0.5 | 662.0% | |
FIIs | % | 3.3 | 0.5 | 675.5% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 63.1 | 27.3 | 231.5% | |
Shareholders | 20,114 | 9,425 | 213.4% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare VIMTA LABS With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB MANKIND PHARMA
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | VIMTA LABS | KREBS BIOCHEMICALS |
---|---|---|
1-Day | -0.59% | 0.13% |
1-Month | 39.83% | -0.23% |
1-Year | 78.13% | 2.24% |
3-Year CAGR | 29.37% | -18.90% |
5-Year CAGR | 49.68% | -1.23% |
* Compound Annual Growth Rate
Here are more details on the VIMTA LABS share price and the KREBS BIOCHEMICALS share price.
Moving on to shareholding structures...
The promoters of VIMTA LABS hold a 36.9% stake in the company. In case of KREBS BIOCHEMICALS the stake stands at 72.7%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of VIMTA LABS and the shareholding pattern of KREBS BIOCHEMICALS.
Finally, a word on dividends...
In the most recent financial year, VIMTA LABS paid a dividend of Rs 2.0 per share. This amounted to a Dividend Payout ratio of 10.8%.
KREBS BIOCHEMICALS paid Rs 0.0, and its dividend payout ratio stood at -0.0%.
You may visit here to review the dividend history of VIMTA LABS, and the dividend history of KREBS BIOCHEMICALS.
Indian benchmark indices remained positive as the session progressed and ended the day on firm footing.